Cargando…

Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis

Neoadjuvant chemotherapy is considered a new treatment option for potentially resectable pancreatic cancer. However, data are not well established on overall survival and delaying surgery in resectable pancreatic cancer, as well as on those patients that ultimately cannot undergo surgery. We analyze...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uson Junior, Pedro Luiz Serrano, Carvalho, Leonardo, Fernandes, Milena Lourenço Coleta, Botrus, Gehan, de Souza Martins, Rodrigo, da Silva, Elaine Ferreira, dos Santos, Sarah Silva Mello Batista, Taniwaki, Leticia, Taranto, Patrícia, Dutra, Ana Carolina Pereira, de Oliveira Filho, João Bosco, Araujo, Sergio Eduardo Alonso, Moura, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365816/ https://www.ncbi.nlm.nih.gov/pubmed/35948602 http://dx.doi.org/10.1038/s41598-022-17743-6

Ejemplares similares

Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives
por: Zugman, Miguel, et al.
Publicado: (2022)

Increasing Stress to Induce Apoptosis in Pancreatic Cancer via the Unfolded Protein Response (UPR)
por: Botrus, Gehan, et al.
Publicado: (2022)

Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report
por: Dias e Silva, Douglas, et al.
Publicado: (2023)

Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials
por: Nahleh, Zeina, et al.
Publicado: (2019)

Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
por: Botrus, Gehan, et al.
Publicado: (2022)

Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
por: Ono, Kosuke, et al.
Publicado: (2021)

Neoadjuvant therapy or upfront surgery in advanced endometrial cancer: a systematic review protocol
por: McCarthy, Amy, et al.
Publicado: (2021)

The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer
por: Zwart, Eline S., et al.
Publicado: (2023)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review
por: Ren, Xiaohan, et al.
Publicado: (2019)

Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis
por: Bradley, Alison, et al.
Publicado: (2019)

Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis
por: Liu, Zhen, et al.
Publicado: (2022)

Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer
por: Jeon, Hyun Jeong, et al.
Publicado: (2023)

The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study
por: Su, Yung-Yeh, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials
por: Ghanem, I., et al.
Publicado: (2022)

Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
por: Bradley, Alison, et al.
Publicado: (2019)

Upfront surgery in patients with epithelial ovarian cancer and enlarged supradiaphragmatic lymph nodes associated with comparable to neoadjuvant chemotherapy
por: Weitzner, Omer, et al.
Publicado: (2022)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

Comparison between upfront surgery and neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A systematic review
por: Fiflis, Stylianos, et al.
Publicado: (2023)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials
por: Uson Junior, P.L.S., et al.
Publicado: (2023)

A commentary on ‘The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study’
por: Chen, Yuan, et al.
Publicado: (2023)

Disparities in Metabolic Conditions and Cancer Characteristics among Hispanic Women with Breast Cancer: A Multi-Institutional Study
por: Jabbal, Iktej S., et al.
Publicado: (2022)

DEBATE UPFRONT vs DELAYED TRANSPLANT
por: Gay, F.
Publicado: (2023)

Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment
por: Fujii, Tsutomu, et al.
Publicado: (2015)

Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: A retrospective, propensity score-matched study
por: Li, Yang, et al.
Publicado: (2020)

Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Jung, Hye-Sol, et al.
Publicado: (2022)

Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis
por: Chen, Xing, et al.
Publicado: (2017)

Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
por: Ratnayake, Bathiya, et al.
Publicado: (2020)

Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications
por: Deig, Christopher Ryan, et al.
Publicado: (2022)

Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis
por: Yang, Zijiao, et al.
Publicado: (2023)

Comparing outcomes between neoadjuvant hormonal therapy followed by prostatectomy versus upfront prostatectomy in high-risk prostate cancer: The road ahead
por: Bhargava, Priyank
Publicado: (2023)

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
por: Gavriatopoulou, Maria, et al.
Publicado: (2020)

Surgery for Crohn’s disease: upfront or last resort?
por: Ahmed Ali, U, et al.
Publicado: (2022)

Postoperative morbidity and mortality after neoadjuvant chemotherapy versus upfront surgery for locally advanced gastric cancer: a propensity score matching analysis
por: Wu, Liucheng, et al.
Publicado: (2019)

Early response to upfront neoadjuvant chemotherapy (CAPOX) alone in low- and intermediate-risk rectal cancer: a single-arm phase II trial
por: Deng, Xiangbing, et al.
Publicado: (2021)

The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis
por: Sonbol, Mohamad Bassam, et al.
Publicado: (2022)

Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature
por: Guo, Marissa, et al.
Publicado: (2021)

Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review
por: Boulva, Kerianne, et al.
Publicado: (2021)

Short-term Outcomes After Upfront Chemotherapy Followed by Curative Surgery in Metastatic Colon Cancer: A Comparison With Upfront Surgery Patients
por: Han, Myung Hyun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_33gccpuf29i3ot6j4egf357jfg